Weathering the Storm: A Look at What Happened to the Class of 2000 IPOs
This article was originally published in Start Up
Executive Summary
It's no secret that biotech's IPO class of 2000 has suffered. Even given the market's rise in the 2nd quarter of 2003, these companies have lost an average of 40% of their market cap over three years.